<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Entresto</title>
    <link rel="stylesheet" href="assets/css/bootstrap.min.css">
    <link rel="stylesheet" href="assets/css/style.css">


</head>

<body>


    <header id="header">
        <div class="header-top text-14">
            <div
                class="container text-center d-sm-flex align-items-center align-items-lg-start justify-content-between ">
                <a href="/" class="logo">
                    <img src="assets/images/logo.svg" alt="">
                </a>
                <div class="d-lg-flex mt-3">
                    <p class="text-color-primary mb-1 mb-lg-0">
                        For Canadian Healthcare Professionals
                    </p>
                    <div class="text-color-primary d-sm-flex align-items-start">
                        <a href="important-safety-information.html">
                            Important Safety Information
                        </a>
                        </a>
                        <a href="#">
                            Francais
                        </a>
                    </div>
                </div>
            </div>
        </div>
        <nav class="navbar navbar-expand-lg navbar-light bg-dark">
            <div class="container">
                <button class="navbar-toggler ms-auto" type="button" data-bs-toggle="collapse"
                    data-bs-target="#navbarSupportedContent" aria-controls="navbarSupportedContent"
                    aria-expanded="false" aria-label="Toggle navigation">
                    <span class="navbar-toggler-icon">
                        <svg viewBox="0 0 24 24" fill="#fff">
                            <path d="M3 18h18v-2H3v2zm0-5h18v-2H3v2zm0-7v2h18V6H3z"></path>
                        </svg>
                    </span>
                </button>
                <div class="collapse navbar-collapse" id="navbarSupportedContent">
                    <ul class="navbar-nav">
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-efficacy.html">
                                Efficacy Data
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-safety-profile.html">
                                Safety Profile
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-dosing.html">
                                Dosing
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-moa.html">
                                Mechanism of Action
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link active" href="hf-guidelines.html">
                                Guidelines
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-resources.html">
                                Resources
                            </a>
                        </li>
                    </ul>
                </div>
            </div>
        </nav>
        <div class="header-bottom"></div>
    </header>

    <section class="page-content hf-guidelines">
        <div class="container">
            <h2 class="common-title-1">
                2021 CCS/CHFS Heart Failure Guidelines Update: <br>
                Selected Highlights
            </h2>
            <div class="mb-5 pb-4">
                <h3 class="pb-2">
                    Updated treatment algorithm for the management of HFrEF from the 2021 CCS/CHFS Heart Failure
                    Guidelines
                    Update<sup>3†</sup>
                </h3>
                <div class="guideline mt-4">
                    <div class="left text-white">
                        <p class="text-uppercase">
                            <span>
                                Treat comorbidities per ccs hf recommendations (INCL.AF,functional mr, Iron Def, Ckd,DM)
                            </span>
                        </p>
                        <p class="text-uppercase">
                            <span>
                                Treat comorbidities per ccs hf recommendations (INCL.AF,functional mr, Iron Def, Ckd,DM)
                            </span>
                        </p>
                    </div>
                    <div class="middle">
                        <div>
                            <h4>
                                HFrEF: LVEF ≤40% AND SYMPTOMS
                            </h4>
                            <h5>
                                Initiate Standard Therapies
                            </h5>
                        </div>
                        <div class="row top-items">
                            <div class="col-md-6 col-lg-3">
                                <div>
                                    <p class="gray">
                                        <strong>ARNI</strong> or <br/>
                                        <strong>ACEi/ARB</strong> <br>
                                        then substitute <br> for<strong>ARNI<sup>‡</sup></strong>
                                    </p>
                                </div>
                            </div>
                            <div class="col-md-6 col-lg-3">
                                <div>
                                    <p class="gray">
                                        <strong>
                                            BETA <br>
                                            BLOCKER
                                        </strong>
                                    </p>
                                </div>
                            </div>
                            <div class="col-md-6 col-lg-3">
                                <div>
                                    <p class="gray">
                                        <strong>
                                            MRA
                                        </strong>
                                    </p>
                                </div>
                            </div>
                            <div class="col-md-6 col-lg-3">
                                <div>
                                    <p class="text-bold gray-text">
                                        SGLT2 <br>
                                        INHIBITOR<sup>†</sup>
                                    </p>
                                </div>
                            </div>
                        </div>
                        <div class="text-center">
                            <img src="assets/images/icons/2.svg" alt="">
                        </div>
                        <p class="text-center para-1 mb-2 text-bold text-24 mt-4">
                            Assess Clinical Factors for Additional Interventions
                        </p>
                        <div class="middle-items mb-3">
                            <div class="row middle-items">
                                <div class="col-md-6 col-lg-3">
                                    <div>
                                        <h5>
                                            <strong>
                                                HR &gt;70 bpm and <br>
                                                sinus rhythm
                                            </strong>
                                        </h5>
                                        <ul>
                                            <li>
                                                <span>•</span>
                                                Consider <br>
                                                <span>
                                                    ivabradine<sup>§</sup>
                                                </span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="col-md-6 col-lg-3">
                                    <div>
                                        <h5>
                                            <strong>
                                                Recent HF <br>
                                                hospitalization
                                            </strong>
                                        </h5>
                                        <ul>
                                            <li class="d-flex">
                                                <span>•</span>&nbsp;Refer to CCS <br>
                                                Guidelines <br>
                                                for complete <br>
                                                considerations
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="col-md-6 col-lg-3">
                                    <div>
                                        <h5>
                                            <strong> Black patients on optimal GDMT,
                                                or patients unable to tolerate
                                                ARNI/ACE/ARB
                                            </strong>
                                        </h5>
                                        <ul>
                                            <li class="d-flex">
                                                <span>•</span>&nbsp;Consider combination <br>
                                                hydralazine-nitrates
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="col-md-6 col-lg-3">
                                    <div>
                                        <h5>
                                            <strong>
                                                Suboptimal rate <br>
                                                control for AF, or <br>
                                                persistent symptoms <br>
                                                despite optimized <br>
                                                GDMT
                                            </strong>
                                        </h5>
                                        <ul>
                                            <li class="d-flex">
                                                <span>•</span>&nbsp;Consider digoxin
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <p class="text-center text-18 mb-3 pb-1">
                            <i>Initiate standard therapies as soon as possible and titrate every 2-4 weeks to target <br>
                                or maximally tolerated dose over 3-6 months</i>
                        </p>
                        <div class="text-center">
                            <img src="assets/images/icons/2.svg" alt="">
                            <p class="text-bold text-24 my-3">
                                Reassess LVEF, Symptoms, Clinical Risk
                            </p>
                        </div>
                        <div class="row bottom-items">
                            <div class="col-md-6 col-lg-4">
                                <div>
                                    <img src="assets/images/icons/2.svg" alt="">
                                    <h3>
                                        NYHA III/IV, Advanced HF <br>
                                        or High-Risk Markers
                                    </h3>
                                    <div class="text-start">
                                        <div>
                                            <h4>
                                                CONSIDER
                                            </h4>
                                            <ul class="gray-text">
                                                <li>
                                                    • Referral for advanced <br>
                                                    HF therapy (mechanical
                                                    circulatory support/
                                                    transplant)
                                                </li>
                                                <li>
                                                    • Referral for supportive/
                                                    palliative care
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-6 col-lg-4">
                                <div>
                                    <img src="assets/images/icons/2.svg" alt="">
                                    <h3>
                                        LVEF ≤35% and <br>
                                        NYHA I-IV (ambulatory)
                                    </h3>
                                    <div>
                                        <p class="gray-text">
                                            Refer to CCS CRT/ICD <br>
                                            recommendations
                                        </p>
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-6 col-lg-4">
                                <div>
                                    <img src="assets/images/icons/2.svg" alt="">
                                    <h3>
                                        LVEF >35%, NYHA I, and <br> Low Risk
                                    </h3>
                                    <div>
                                        <p class="gray-text">
                                            Continue present <br>
                                            management, reassess as <br>
                                            needed

                                        </p>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="right">
                        <p class="text-uppercase text-white">
                            <span>
                                Treat comorbidities per ccs hf recommendations (INCL.AF,functional mr, Iron Def, Ckd,DM)
                            </span>
                        </p>
                        <p class="text-uppercase">
                            <span>
                                Treat comorbidities per ccs hf recommendations (INCL.AF,functional mr, Iron Def, Ckd,DM)
                            </span>
                        </p>
                    </div>
                </div>
            </div>
            <div class="common-block-3">
                <p>
                    “Standard therapies are applicable to most patients with HFrEF for reducing cardiovascular mortality
                    and hospitalization for HF.”<sup>3</sup>
                </p>
            </div>
            <div class="common-block-3">
                <p>
                    “Every attempt should be made to initiate and titrate therapies with the goal of medication
                    optimization by 3–6 months after a diagnosis of HFrEF.”<sup>3</sup>
                </p>
            </div>
            <br>
            <div class="common-block-4 mt-4">
                <h3>
                    2021 CCS recommendation<sup>†</sup>
                </h3>
                <div class="common-block-3">
                    <p>
                        <strong>
                            ARNI: Recommended as a standard therapy for HFrEF
                        </strong>
                        <span>
                            “The 2021 CCS HF Guidelines recommend ARNI as a standard therapy for HFrEF, in combination
                            with
                            other standard therapies.”<sup>3</sup>
                        </span>
                    </p>

                </div>
            </div>
            <div class="common-block-4">
                <h3>
                    2021 CCS recommendation<sup>†</sup>
                </h3>
                <div class="common-block-3">
                    <p>
                        <span>
                            “We recommend that an ARNI be used in place of an ACEi or ARB, in patients with HFrEF, that
                            remain symptomatic despite treatment with appropriate doses of GDMT… (was assigned strong
                            recommendation, high-quality evidence).”<sup>3</sup>
                        </span>
                    </p>

                </div>
            </div>
            <div class="common-block reference-block">
                <p>
                    <span>
                        † Please consult guidelines for complete recommendations.<sup>3</sup>
                    </span>
                    <span>
                        ‡ ARNI and SGLT2 inhibitor are not indicated as first-line treatments for HFrEF. Please refer to
                        the separate Product Monographs for
                        complete prescribing information.
                    </span>
                    <span>
                        § Ivabradine is indicated in patients with HFrEF and HR ≥77 bpm in sinus rhythm.
                    </span>
                    <span>
                        ACEi: angiotensin converting enzyme inhibitor; AF: atrial fibrillation; ARB: angiotensin
                        receptor
                        blocker; ARNI: angiotensin receptor-neprilysin inhibitor; CCS: Canadian Cardiovascular Society;
                        CHFS: Canadian Heart Failure Society; CKD: chronic kidney disease; CRT: cardiac
                        resynchronization
                        therapy; DM: diabetes mellitus; GDMT: guideline-directed medical therapy; HFrEF: heart failure
                        with
                        reduced ejection fraction; HR: heart rate; ICD: implantable cardioverter defibrillator; LVEF:
                        left
                        ventricular ejection fraction; MR: mitral regurgitation; MRA: mineralocorticoid receptor
                        antagonist;
                        NYHA: New York Heart Association; SGLT: sodium glucose transport.
                    </span>
                </p>
            </div>
        </div>
    </section>

    <footer>
        <div class="container">
            <div class="links text-center text-lg-start mb-4 mb-lg-0">
                <a href="privacy-policy.html">
                    Privacy Policy
                </a>
                |
                <a href="terms-of-use.html">
                    Terms of Use
                </a>
                | <a href="#">
                    Cookie Settings
                </a>
            </div>
            <div class="d-flex align-items-lg-end flex-column flex-lg-row">
                <a href="#">
                    <img src="assets/images/footer-logo.svg" alt="">
                </a>
                <p class="mt-3 mt-lg-0">
                    Entresto is a registered trademark. <br>
                    © Novartis Pharmaceuticals Canada Inc. 2022
                </p>
                <div class="footer-right mt-2 mt-lg-0">
                    <p class="mb-3 mb-lg-0">
                        187298E - July 2022
                    </p>
                    <img src="assets/images/footer-img-2.svg" alt="">
                    <img src="assets/images/footer-img-3.svg" alt="">
                </div>
            </div>
        </div>
    </footer>

    <script src="assets/js/jquery.js"></script>
    <script src="assets/js/bootstrap.bundle.min.js"></script>
    <script src="assets/js/index.js"></script>
</body>

</html>